OR WAIT null SECS
August 02, 2008
CMOs expand capacity and capabilities in high-potency manufacturing to meet strong demand for cytotoxic and other potent drugs.
July 02, 2008
The year 2007 was slow for approvals for new molecular entities and overall pharmaceutical industry growth. Big Pharma seeks relief in a growing biologics portfolio.
June 02, 2008
Antibody drug conjugates offer a niche opportunity in drug development and contract manufacturing.
May 02, 2008
Chemocatalytic and biocatalytic routes show promise for more efficient syntheses of select active ingredients.
March 02, 2008
The European Union's REACH initiative has the potential to affect the flow of chemicals into the pharmaceutical suppy chain.
February 02, 2008
Contract manufacturers expand capabilities in aseptic processing, clinical-trial materials supply, and cytotoxic manufacturing.
January 02, 2008
Researchers and process chemists share approaches in synthesis of active ingredients and pharmaceutical intermediates.
December 01, 2007
The permeation of drugs through the skin is compromised by the presence of polar functional groups such as thiols, alcohols, phenols, imides or amides. By transiently masking these polar functional groups as prodrugs the permeability of drugs containing these functional groups through the skin can be improved.
November 02, 2007
Market demand for cytotoxic drugs is leading CMOs to expand their API manufacturing and formulation services.
October 02, 2007
Orally disintegrating tablets (ODTs) continue to attract attention as an alternative to conventional oral dosage forms.